Authors

Latest:

Dr Aerts on the Rationale for the DENIM Trial in Mesothelioma

Joachim G. J. V. Aerts, MD, PhD, discusses the rationale for conducting the phase 3 DENIM trial in patients with mesothelioma, highlighting the importance of focusing investigational efforts onto the dendritic cells.

UPMC Hillman Cancer Center

Latest:

Illumination of Immune Checkpoint LAG3 ‘Black Box’ Could Yield New Cancer and Autoimmune Therapies

A new study pinpoints how LAG3 modulates T cell activity, providing important insights for development of other LAG3-blocking therapies for cancer and autoimmune disorders.

Deb Schrag, MD, MPH

Latest:

Dr Schrag on Neoadjuvant Chemotherapy and Selective Chemoradiation in Locally Advanced Rectal Cancer

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania

Latest:

MET Inhibitors in NSCLC: Toxicity Management

Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.

Marc-Oliver Grimm, MD

Latest:

Dr Grimm on the Rationale for Conducting a Post-Hoc Analysis of ARASENS in mHSPC

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Elizabeth A. Brem, MD

Latest:

Dr Brem on Odronextamab in Previously Untreated Patients, High-Risk Follicular Lymphoma

Elizabeth Brem, MD, discusses data for odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma.

Stephanie J. Lee, MD, MPH

Latest:

Dr. Lee on the Results of the REACH3 Trial in Chronic GVHD

Stephanie J. Lee, MD, MPH, discusses the results of the phase 3 REACH3 trial in chronic graft-vs-host disease.

Andrew Coveler, MD

Latest:

Dr. Coveler on Replacing 5-FU With NUC-3373 in mCRC

Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.

Anna B. Halpern, MD

Latest:

Dr Halpern on Addressing Unmet Needs in Myelofibrosis

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.

Carrie Lynn Kitko, MD

Latest:

Dr Kitko on the Utility of Obe-Cel in Pediatric Patients With B-ALL

Carrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Sushmita Gordhandas, MD

Latest:

Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary Collaboration

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

Dionisia Quiroga, DO, PhD

Latest:

Dr Quiroga on the Emergence of HER2-Low in Breast Cancer

Dionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.

Seth Wander, MD, PhD

Latest:

Dr Wander on Managing HR+ Advanced Breast Cancer in the Clinic

Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.

Shuo Ma, MD, PhD

Latest:

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Yiming Wu, PhD

Latest:

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Vadim S. Koshkin, MD

Latest:

Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies

UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.

Pamela J. Sung, MD, PhD

Latest:

Differentiation Therapy in Acute Myeloid Leukemia: Not Just for APL Anymore

Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.

Edward Kim, MD, Mount Sinai Medical Center

Latest:

Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCC

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.

Keiichi Fujiwara, MD, PhD

Latest:

Dr Fujiwara on the FDA Approval of Tisotumab Vedotin for Recurrent Cervical Cancer

Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.

Alessandro Villa, DDS, PhD, MPH

Latest:

The Importance of Oral Medicine in Cancer: Evaluation and Treatment

Alessandro Villa, DDS, PhD, MPH, discusses the importance of oral medicine in cancer treatment.